Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke: Gosselies, Belgium Saturday, December 21, 2024, 15:00 Hrs [IST] Bioxodes SA, ...

MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.

The "Dengue Fever - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of the Dengue Fever Clinical trials scenario ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks InflaRx ( (IFRX) ) has issued an update.

Each of the two parts of the Phase 2a trial of DA-1241 were designed ... For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815. About DA-1241 DA-1241 ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide developed from tick saliva Gosselies (Belgium), 19 2024 (08:30 CET) ...

Each of the two parts of the Phase 2a trial of DA-1241 were designed to be 16-week ... levels at Week 16. For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815.

The company elected not to start three Phase 1b/2a trials in spinal cord injury, multiple sclerosis and Alzheimer’s disease as it originally set out to do, but instead chose to focus on spinal ...

"Achieving the primary endpoint of a reduction in ALT levels through direct hepatic effects, as well as notable secondary endpoints, including significantly lower HbA1C levels compared to the placebo, ...